Stay updated with breaking news from First Line Maintenance. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
07.12.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, for ...
WILMINGTON, Del.--(BUSINESS WIRE)--Oct 21, 2023--
First Phase 3 survival data from KEYNOTE-A39/EV-302 support potential benefit of combination approach in previously untreated locally advanced or metastatic urothelial cancer; data are selected for...
A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.
Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA (olaparib), IMFINZI(durvalumab), chemotherapy and bevacizumab demonstrated